Straight from the Desk
Syz the moment
Live feeds, charts, breaking stories, all day long.
- All
- us
- macro
- equities
- Food for Thoughts
- sp500
- Central banks
- Bonds
- bitcoin
- Asia
- markets
- technical analysis
- investing
- europe
- Crypto
- tech
- geopolitics
- Commodities
- AI
- gold
- performance
- ETF
- nvidia
- earnings
- Forex
- Real Estate
- oil
- banking
- Volatility
- apple
- nasdaq
- magnificent-7
- emerging-markets
- energy
- Alternatives
- switzerland
- china
- trading
- tesla
- sentiment
- russia
- Money Market
- assetmanagement
- UK
- ESG
- Middle East
- amazon
- ethereum
- meta
- microsoft
- bankruptcy
- Healthcare
- Industrial-production
- Turkey
- Global Markets Outlook
- africa
- brics
- Market Outlook
- Asset Allocation Insights
- Flash
- Focus
New weight-loss drug ETF
“Roundhill Investments' GLP-1 & Weight Loss ETF (OZEM), which began trading last week, pairs leaders Eli Lilly and Novo Nordisk with players developing new treatments for weight loss and diabetes. CEO Dave Mazza said his firm is capitalizing on explosive growth potential in the industry…Eli Lilly and Novo Nordisk each hold a roughly 20% weighting in the ETF. The three next largest positions are Zealand Pharma, Amgen and Chugai Pharmaceutical, each of which have a weighting under 5%”. Source: CNBC, Bloomberg
(Bloomberg) - A surprising thing is happening to some women on weight-loss drugs who’ve struggled with fertility issues: They’re getting pregnant...
Source: Bloomberg, Carl Quintanilla
Investing with intelligence
Our latest research, commentary and market outlooks